Radiopharmaceutical company Fusion Pharmaceuticals Inc. is acquiring a phase II actinium-based alpha-emitter radiopharma program for prostate cancer from Radiomedix Inc.
Receptor-interacting serine/threonine-protein kinase 2 (RIPK2) is a kinase protein that plays key roles in inflammation and antimicrobial response through the NF-kB signaling pathway, as well as it is known to activate c-MYC, which is involved in the progression of several malignancies, such as prostate cancer.
In advanced or metastatic prostate cancer (PCa), patients may reach a stage where they do not respond to therapy. This stage is associated with chromosomal instability (CIN) and allow cells, up to a certain threshold, to adapt to therapy. However, a Mayo Clinic study has found a way to push that line so that cancer cells are so aberrant that they die.
Nido Biosciences Inc. has synthesized bicyclic compounds acting as selective androgen receptor modulators (SARMs) reported to be useful for the treatment of spinal and bulbar muscular atrophy, neurodegeneration and cancer.
Dxcover Ltd. raised $9.25 million (£7.5 million) in a series A fundraising round and received a grant of $2.7 million (£2.2 million) from the European Innovation Council to support development of the company’s liquid biopsy platform for the detection of multiple early-stage cancers. Existing investors Eos Advisory LLP, Mercia Asset Management plc, Scottish Enterprise, University of Strathclyde, SIS Ventures and Norcliffe Capital led the round, which was also joined by Mark Banforth of Thairm Bio.
Recurv Pharma Inc. is set to receive investment of up to $24 million from TVM Capital Life Science GmbH to support development up to phase IIa proof of concept of RP-001 to treat solid tumors.
New York-based Paige.AI Inc., was successful in its de novo application to the U.S. FDA for the company’s digital pathology software for identification of cancerous prostate tissue, but the agency needed nearly a year and a half after the September 2021 grant of de novo petition to post the regulation for this novel algorithm.
Shanghai University of Traditional Chinese Medicine and Vestlandets Innovasjonsselskap AS (VIS) have disclosed bufalin derivatives acting as androgen receptor antagonists reported to be useful for the treatment of prostate cancer.
Researchers from Guangzhou Institutes of Biomedicine and Health and CSIRO presented the discovery and preclinical characterization of novel compounds with high activity against androgen receptor (AR)-dependent prostate cancer cells.
Medshine Discovery Inc. has identified proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to an androgen receptor targeting moiety via a linker acting as androgen receptor degradation inducers reported to be useful for the treatment of cancer.
